Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.

Abstract

Imatinib mesylate is a receptor kinase inhibitor approved by the Food and Drug Administration for the treatment of malignant metastatic and/or unresectable gastrointestinal stromal tumors and chronic myelogenous leukemia. Although imatinib is generally well tolerated, certain adverse drug reactions are common. These include gastrointestinal side-effects such as diarrhea, nausea and vomiting, as well as hematological side-effects and other miscellaneous side-effects such as fatigue, edema, dermatitis and dyspnea. We present a previously unreported adverse effect of imatinib, gastric antral vascular ectasia, in a 74-year-old woman with gastrointestinal stromal tumor in remission treated with adjuvant imatinib. Endoscopy performed prior to starting imatinib showed normal gastric mucosa, but 8 months after starting imatinib showed diffuse gastric inflammation. Repeat endoscopy 1 month after discontinuing imatinib showed significant improvement in gastric inflammation.

• Authors: Ehab Saad Aldin, Fadi Mourad, Arafat Tfayli
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 42 Issue 5 Pg. 447-50 (May 2012) ISSN: 1465-3621 [Electronic] England
• PMID: 22422898 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Benzamides
• Piperazines
• Protein Kinase Inhibitors
• Pyrimidines
• Imatinib Mesylate
• Protein-Tyrosine Kinases

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Benzamides
• Endoscopy, Digestive System
• Female
• Gastric Antral Vascular Ectasia (chemically induced, complications)
• Gastrointestinal Hemorrhage (chemically induced, etiology)
• Gastrointestinal Neoplasms (drug therapy, pathology)
• Gastrointestinal Stromal Tumors (drug therapy, pathology)
• Humans
• Imatinib Mesylate
• Liver Neoplasms (drug therapy, secondary)
• Piperazines (administration & dosage, adverse effects)
• Protein Kinase Inhibitors (adverse effects)
• Protein-Tyrosine Kinases (antagonists & inhibitors)
• Pyrimidines (administration & dosage, adverse effects)